In The Clinic Archives - Page 3 of 7 - Cancer Therapy Advisor

Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer.

Treating Hypercalcemia in Patients with Cancer

By

February 4, 2015

Hypercalcemia is one of the most common laboratory abnormalities in patients with cancer, and oncologists should know how to identify and treat it.

Brain Cancer

Managing Anticoagulation in Patients with Brain Tumors

By

C. Andrew Kistler, MD, PharmD

January 15, 2015

Patients with brain cancer are at increased risk of deep vein thrombosis and consequently pulmonary embolism.

Monitoring Chemo Patients for Cadiotoxicity

General Oncology

Cardiotoxicity Associated With Monoclonal Antibody Chemotherapy

By

C. Andrew Kistler, MD, PharmD

December 23, 2014

Surveillance for cardiotoxicity must be a part of treating patients with monoclonal antibodies.

Underlying malignancy is a potential cause of nonbacterial thrombotic endocarditis.

General Oncology

Nonbacterial Thrombotic Endocarditis and Malignancy

By

C. Andrew Kistler, MD, PharmD

December 15, 2014

Underlying malignancy is a potential cause of nonbacterial thrombotic endocarditis, understanding symptoms and treatment options is important.

Fever is a common symptom for patients with cancer who have neutropenia.

General Oncology

MDRO Infections in Patients with Neutropenic Fever

By

C. Andrew Kistler, MD, PharmD

December 1, 2014

Fever is a common symptom for patients with cancer who have neutropenia and it is often difficult to determine if they are in infectious in etiology.

Oncology clinicians must balance the cost, benefit, and risk when comparing inpatient vs. outpatient

General Oncology

Inpatient Versus Outpatient Cancer Therapy: Costs, Benefits, and Risks

By

Jason Hoffman, PharmD, RPh

November 18, 2014

Oncology clinicians must balance the cost, benefit, and risk when comparing inpatient versus outpatient care for patients.

Iniparib plus gemcitabine and carboplatin did not meet criteria for the primary endpoints.

Breast Cancer

Iniparib May Be Effective as Salvage Therapy for Metastatic Triple-Negative Breast Cancer

By

Jason Hoffman, PharmD, RPh

November 4, 2014

Despite promising results, iniparib was found to be ineffective as first-line therapy for patients with metastatic triple-negative breast cancer.

Rolapitant + granisetron and dexamethasone is effective in preventing chemo-induced nausea, vomiting

General Oncology

Rolapitant Proves Effective for the Prevention of Chemotherapy-Induced Nausea and Vomiting

By

Jason Hoffman, PharmD, RPh

October 21, 2014

Rolapitant in combination with granisetron and dexamethasone is effective in preventing chemotherapy-induced nausea and vomiting.

New regimen resulted in less chemotherapy-induced nausea and vomiting.

Multiple Myeloma

Aprepitant for the Prevention of Chemotherapy-Induced Nausea, Vomiting in Multiple Myeloma

By

Jason Hoffman, PharmD, RPh

October 7, 2014

New regimen resulted in significantly less chemotherapy-induced nausea and vomiting in multiple myeloma patients.

Patients with NF-1 are up to 4 times more likely to get both benign and malignant neoplasms.

General Oncology

Malignancies in Patients With Neurofibromatosis Type 1 (NF-1)

By

C. Andrew Kistler, MD, PharmD

September 16, 2014

Patients with NF-1 are up to 4 times more likely to get both benign and malignant neoplasms, in the muscles, skin, and gastrointestinal tract.